Echo Therapeutics, Ferndale Pharma Group deal

The partners added Argentina, Brazil, Chile, Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland, Austria, Australia and New Zealand to a 2009 deal granting Ferndale exclusive rights to develop and commercialize Prelude SkinPrep System in North America and the U.K. for transdermal analgesic and anesthetic drug delivery applications. Ferndale will use Prelude for skin preparation prior to application of Ferndale's marketed LMX lidocaine 4% topical anesthetic cream. Echo is eligible for milestone payments upon regulatory approval in all countries excluding New Zealand, plus additional milestones and escalating royalties. Details were not disclosed (see BioCentury, June 8, 2009). ...